Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis

被引:750
|
作者
Chan, TM [1 ]
Li, FK [1 ]
Tang, CSO [1 ]
Wong, RWS [1 ]
Fang, GX [1 ]
Ji, YL [1 ]
Lau, CS [1 ]
Wong, AKM [1 ]
Tong, MKL [1 ]
Chan, KW [1 ]
Lai, KN [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Nephrol, Hong Kong, Hong Kong, Peoples R China
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2000年 / 343卷 / 16期
关键词
D O I
10.1056/NEJM200010193431604
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The combination of cyclophosphamide and prednisolone is effective for the treatment of severe lupus nephritis but has serious adverse effects. Whether mycophenolate mofetil can be substituted for cyclophosphamide is not known. Methods: In 42 patients with diffuse proliferative lupus nephritis we compared the efficacy and side effects of a regimen of prednisolone and mycophenolate mofetil given for 12 months with those of a regimen of prednisolone and cyclophosphamide given for 6 months, followed by prednisolone and azathioprine for 6 months. Complete remission was defined as a value for urinary protein excretion that was less than 0.3 g per 24 hours, with normal urinary sediment, a normal serum albumin concentration, and values for serum creatinine and creatinine clearance that were no more than 15 percent above the base-line values. Partial remission was defined as a value for urinary protein excretion that was between 0.3 and 2.9 g per 24 hours, with a serum albumin concentration of at least 3.0 g per deciliter. Results: Eighty-one percent of the 21 patients treated with mycophenolate mofetil and prednisolone (group 1) had a complete remission, and 14 percent had a partial remission, as compared with 76 percent and 14 percent, respectively, of the 21 patients treated with cyclophosphamide and prednisolone followed by azathioprine and prednisolone (group 2). The improvements in the degree of proteinuria and the serum albumin and creatinine concentrations were similar in the two groups. One patient in each group discontinued treatment because of side effects. Infections were noted in 19 percent of the patients in group 1 and in 33 percent of those in group 2 (P=0.29). Other adverse effects occurred only in group 2; they included amenorrhea (in 23 percent of the patients), hair loss (19 percent), leukopenia (10 percent), and death (10 percent). The rates of relapse were 15 percent and 11 percent, respectively. Conclusions: For the treatment of diffuse proliferative lupus nephritis, the combination of mycophenolate mofetil and prednisolone is as effective as a regimen of cyclophosphamide and prednisolone followed by azathioprine and prednisolone. (N Engl J Med 2000;343:1156-62.) (C) 2000 Massachusetts Medical Society.
引用
收藏
页码:1156 / 1162
页数:7
相关论文
共 50 条
  • [21] Effects of mycophenolate mofetil for patients with crescentic lupus nephritis
    Tang, Zheng
    Yang, Guang
    Yu, Chen
    Yu, Yusheng
    Wang, Jinquan
    Hu, Weixin
    Zeng, Caihong
    Chen, Huiping
    Liu, Zhihong
    Li, Leishi
    [J]. NEPHROLOGY, 2008, 13 (08) : 702 - 707
  • [22] Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis
    Chan, TM
    Tse, KC
    Tang, CSO
    Mok, MY
    Li, FK
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (04): : 1076 - 1084
  • [23] Mycophenolate mofetil for lupus nephritis: an update
    Mok, Chi Chiu
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (12) : 1353 - 1364
  • [24] Treatment of Lupus Nephritis by Mycophenolate Mofetil
    Rabrenovic, Violeta
    Poskurica, Mileta
    Kovacevic, Zoran
    Nesic, Vidosava
    Savin, Marina
    Mitic, Branka
    Dimkovic, Nada
    Cuckovic, Cedomir
    Vujic, Danica
    Pljesa, Steva
    Perunicic-Pekovic, Gordana
    Curic, Slobodan
    Mitic, Igor
    Ratkovic, Marina
    Marinkovic, Jelena
    Jovanovic, Dragan
    [J]. KIDNEY & BLOOD PRESSURE RESEARCH, 2010, 33 (04): : 297 - 303
  • [25] Lupus nephritis: treatment with mycophenolate mofetil
    Kapitsinou, PP
    Boletis, JN
    Skopouli, FN
    Boki, KA
    Moutsopoulos, HM
    [J]. RHEUMATOLOGY, 2004, 43 (03): : 377 - 380
  • [26] Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide
    Contreras, G
    Tozman, E
    Nahar, N
    Metz, D
    [J]. LUPUS, 2005, 14 : S33 - S38
  • [27] The mycophenolate mofetil treatment utility for diffuse proliferative lupus nephritis class IV (WHO) in patients without control disease activity.
    Pérez, CM
    Gonzalez, SL
    Camargo, CA
    Hernandez, VR
    Canul, NE
    Fernandez, AG
    Ake, UM
    Medina, RF
    Fraga, MA
    [J]. JOURNAL OF RHEUMATOLOGY, 2006, 33 (02) : 420 - 420
  • [28] Comment on: Efficacy and Safety of Mycophenolate Mofetil versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis
    Ziaie, Shadi
    Moradi, Omid
    Saffaei, Ali
    [J]. IRANIAN JOURNAL OF KIDNEY DISEASES, 2019, 13 (05) : 347 - 347
  • [29] Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?
    Eid M. El-Shafey
    Said H. Abdou
    Mohamed M. Shareef
    [J]. Clinical and Experimental Nephrology, 2010, 14 : 214 - 221
  • [30] Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?
    El-Shafey, Eid M.
    Abdou, Said H.
    Shareef, Mohamed M.
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2010, 14 (03) : 214 - 221